Flamel Technologies Announces Projected Release Date of Third

Flamel Technologies Announces Projected Release Date of Third Quarter
2012 Results and Conference Call 
LYON, FRANCE -- (Marketwire) -- 10/30/12 --  Flamel Technologies
(NASDAQ: FLML) expects to release certain financial results for the
third quarter of 2012, on Monday, November 5th, before the market
open. A conference call to discuss these results has been scheduled
for Monday, November 5th, at 8:30 AM (Eastern Standard Time). A
question and answer period will follow management's prepared remarks. 
To participate in the conference call, investors are invited to dial
888-438-5524. The conference ID number is 9243089. The conference
call webcast may be accessed at www.flamel.com. 
A replay of the call will be available for 14 days, within a few
hours after the call ends. Investors may listen to the replay of the
call by dialing 888-203-1112 (U.S.) or +1-719-457-0820
(international), with the passcode 9243089. A replay of the webcast
will also be archived on Flamel's website for 90 days following the
call. 
About Flamel Technologies. Flamel Technologies SA's (NASDAQ: FLML)
business model is to blend high-value internally developed products
with its leading drug delivery capabilities. The Company has a
proprietary pipeline of niche specialty pharmaceutical products,
while its drug delivery platforms are focused on the goal of
developing safer, more efficacious formulations of drugs to address
unmet medical needs. Its partnered pipeline includes biological and
chemical drugs formulated with the Medusa(R) and Micropump(R)
proprietary drug delivery platforms. Several Medusa-based products
are currently in the clinical stages of development; Medusa's lead
internal product candidate IFN-alpha XL (long-acting interferon
alpha-2b) is being evaluated in a Phase 2b trial in HCV patients. The
Company has developed products and manufactures Micropump-based
microparticles under FDA-audited GMP guidelines. Flamel has
collaborations with a number of leading pharmaceutical and
biotechnology companies, including GlaxoSmithKline (Coreg CR(R),
carvedilol phosphate) and Merck Serono (long acting interferon beta
1a). Flamel is headquartered in Lyon, France and has operations in
St. Louis, Missouri, and manufacturing facilities in Pessac, France.
Additional information ma
y be found at www.flamel.com. 
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
certain plans, expectations, goals and projections regarding
financial results, product developments and technology platforms. All
statements that are not clearly historical in nature are
forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," "will," "may," and similar expressions
are generally intended to identify forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control that could cause
actual results to differ materially from those contemplated in such
forward-looking statements. These risks include risks that the
acquisition of Eclat Pharmaceuticals may not be successfully
integrated or that certain payment acceleration events may be
triggered; the expected timing of the filing of our first New Drug
Application (NDA) with the FDA may be delayed; the identified
opportunities will not result in shorter-term, high value results;
clinical trial results may not be positive or our partners may decide
not to move forward; management transition to a new chief executive
officer may be disruptive or not succeed as planned; products in the
development stage may not achieve scientific objectives or milestones
or meet stringent regulatory requirements; products in development
may not achieve market acceptance; competitive products and pricing
may hinder our commercial opportunities; we may not be successful in
identifying and pursuing opportunities to develop our own product
portfolio using Flamel's technology; and the risks associated with
our reliance on outside parties and key strategic alliances. These
and other risks are described more fully in Flamel's Annual Report on
Form 20-F for the year ended December 31, 2011 that has been filed
with the Securities and Exchange Commission (SEC). All
forward-looking statements included in this release are based on
information available at the time of the release. We undertake no
obligation to update or alter our forward-looking statements as a
result of new information, future events or otherwise. 
Contact: 
Michael S. Anderson 
Phone: 33 (0) 4 72 78 34 34
Fax: 33 (0) 4 72 78 34 35
E-mail: anderson@flamel.com 
 
 
Press spacebar to pause and continue. Press esc to stop.